Skip to content
Company Analysis

Redhill Biopharma Ltd. RDHL

A comprehensive view of key metrics, scores, and financial health for Redhill Biopharma Ltd.

Overview of RedHill Biopharma Ltd.

RDHL NCM
Healthcare Drug Manufacturers - Specialty & Generic Micro Cap
RedHill Biopharma Ltd. (RDHL), is a Micro Cap company, in the Drug Manufacturers - Specialty & Generic industry, last closed at $1.03, about 49.5% overvalued vs fair value, -52.8% 1Y return, ranked 1075/1121 in sector.
$1.03
0.97%
As of April 28, 2026
Previous close • Vol 90d: 84.1%
52-Week Range
Market Cap
$5.20M
Enterprise Value
$2.55M
Overall Score
View breakdown
Overall
Growth
Weak
Profitability
Fair
Health
Weak
Efficiency
Fair
Valuation
Weak
Growth
Weak
Profitability
Fair
Health
Weak
Efficiency
Fair
Valuation
Weak
Completeness: 82%
Confidence: 54%
Updated: Mar 8
Top Beats

Quick Facts

Website https://www.redhillbio.com
HQ Tel Aviv
Employees 35
Fiscal year Dec 31

Next Events

No upcoming events available.

Fair Value Snapshot

Bear Base Bull
$0
$1
$1
Current: $1.03 -50% vs base

Engine Room Money Flow™

Micro Cap

Pharmaceutical / Mature Biotech - Where revenue goes and how value is created

Flow Steps
Total Revenue
$8.0M
23.2%%
Gross Profit
$4.9M
58%%
R&D Expense
$1.6M
-55%%
Operating Income (EBIT)
$-8.2M
-133.8%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Pharmaceutical / Mature Biotech

Quality & Reliability Indicators

R&D Intensity
19.7%
Good

R&D intensity in normal pharma range (15-25%)

Locked Metric
-
Premium
Locked Metric
-
Premium

Where It Leaks

Cash Flow Health critical
Significant cash flow inefficiencies identified. Multiple high-impact leaks require attention.
2
Active Leaks
0/2
Improving
0
High Impact
2
Critical
Locked Leak
Upgrade to view details
Premium
Moat Analysis Corporate Default

Competitive Advantage Assessment

Evaluating Redhill Biopharma Ltd.'s durable competitive advantages across 6 defense dimensions

Overall Moat Strength
30
/100
Developing
Scores based on quantitative metrics and qualitative factors

Upgrade to unlock interactive defense details

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Developing
29
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

Generic Industrial / Default vs Industry Peers 92% Coverage
Trade-Off Triangle Visualization A ternary plot showing RDHL's balance between Growth (34.3%), Profitability (40.8%), and Safety (24.8%). Growth 34% Safety 25% Profitability 41%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

35th percentile vs peers
36
Key Signals
Rev Growth YoY 23.2% 74p EPS Growth YoY -1.07 21p Revenue CAGR 3Y -54.6% 1p
Strengths
  • Superior capital returns - 3 return metrics above peer median
  • ROIC in top 20% of peers (2.62, 96th percentile)
Risks

No significant risks identified for this axis.

Profitability

42th percentile vs peers
42
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

25th percentile vs peers
26
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for Redhill Biopharma Ltd..

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
$0.52
- - -
-49.5% vs current
Snapshot base estimate
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info